Tags

Type your tag names separated by a space and hit enter

α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.
J Gastroenterol Hepatol. 2016 May; 31(5):1001-8.JG

Abstract

BACKGROUND AND AIMS

Eradicating chronic hepatitis C virus (HCV) infection improves liver fibrosis and reduces hepatocellular carcinoma (HCC) incidence in chronic HCV patients. We evaluated the relationship between fibrosis regression, as assessed by sequential biopsies, and clinical factors of patients with sustained virological response (SVR).

METHODS

We retrospectively enrolled 130 patients (74 men; 60.1 ± 8.1 years) with chronic HCV treated with interferon and ribavirin therapy who achieved SVR. To evaluate the change in fibrosis stage over time, all patients underwent a pre-therapy initial biopsy and a second biopsy after achieving SVR.

RESULTS

The mean time between biopsies was 5.5 ± 1.2 years. Fibrosis stage regressed in 55 patients (42.3%), remained stable in 69 (53.1%), and progressed in 6 (4.6%). The mean fibrosis stage significantly decreased, from 2.01 ± 0.99 units to 1.61 ± 1.24 units (P < 0.001). Aspartate aminotransferase, γ-glutamyltransferase, and α-fetoprotein (AFP) levels at 24 weeks after the end of treatment (EOT) were significantly lower, and the platelet count at 24 weeks after the EOT was significantly higher in patients with fibrosis regression than in those without. Logistic regression analysis confirmed that lower AFP levels (< 5.4 ng/mL) at 24 weeks after the EOT (odds ratio [OR], 4.626; 95% confidence interval [CI], 1.557-13.153; P = 0.006) and HCV genotype 2 (OR, 2.198; 95% CI, 1.010-4.786; P = 0.047) were significant independent predictive factors for regressed fibrosis after SVR.

CONCLUSIONS

Lower post-treatment AFP levels and HCV genotype 2 significantly correlated with liver fibrosis regression after SVR.

Authors+Show Affiliations

Department of Gastroenterology, Komaki City Hospital, Komaki, Aichi, Japan.Department of Gastroenterology, Komaki City Hospital, Komaki, Aichi, Japan.Department of Gastroenterology and Hepatology, Nagoya University School of Medicine, Nagoya, Aichi, Japan.Department of Gastroenterology and Hepatology, Nagoya University School of Medicine, Nagoya, Aichi, Japan.Department of Gastroenterology and Hepatology, Nagoya University School of Medicine, Nagoya, Aichi, Japan.Department of Gastroenterology and Hepatology, Nagoya University School of Medicine, Nagoya, Aichi, Japan.Department of Gastroenterology and Hepatology, Nagoya University School of Medicine, Nagoya, Aichi, Japan.Department of Gastroenterology and Hepatology, Nagoya University School of Medicine, Nagoya, Aichi, Japan.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27123974

Citation

Tachi, Yoshihiko, et al. "Α-fetoprotein Levels After Interferon Therapy Predict Regression of Liver Fibrosis in Patients With Sustained Virological Response." Journal of Gastroenterology and Hepatology, vol. 31, no. 5, 2016, pp. 1001-8.
Tachi Y, Hirai T, Ishizu Y, et al. Α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response. J Gastroenterol Hepatol. 2016;31(5):1001-8.
Tachi, Y., Hirai, T., Ishizu, Y., Honda, T., Kuzuya, T., Hayashi, K., Ishigami, M., & Goto, H. (2016). Α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response. Journal of Gastroenterology and Hepatology, 31(5), 1001-8. https://doi.org/10.1111/jgh.13245
Tachi Y, et al. Α-fetoprotein Levels After Interferon Therapy Predict Regression of Liver Fibrosis in Patients With Sustained Virological Response. J Gastroenterol Hepatol. 2016;31(5):1001-8. PubMed PMID: 27123974.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response. AU - Tachi,Yoshihiko, AU - Hirai,Takanori, AU - Ishizu,Youji, AU - Honda,Takashi, AU - Kuzuya,Teiji, AU - Hayashi,Kazuhiko, AU - Ishigami,Masatoshi, AU - Goto,Hidemi, PY - 2015/08/27/received PY - 2015/11/06/revised PY - 2015/11/06/accepted PY - 2016/4/29/entrez PY - 2016/4/29/pubmed PY - 2017/5/18/medline KW - chronic hepatitis C KW - fibrosis KW - sequential biopsy KW - sustained virological response KW - α-fetoprotein SP - 1001 EP - 8 JF - Journal of gastroenterology and hepatology JO - J. Gastroenterol. Hepatol. VL - 31 IS - 5 N2 - BACKGROUND AND AIMS: Eradicating chronic hepatitis C virus (HCV) infection improves liver fibrosis and reduces hepatocellular carcinoma (HCC) incidence in chronic HCV patients. We evaluated the relationship between fibrosis regression, as assessed by sequential biopsies, and clinical factors of patients with sustained virological response (SVR). METHODS: We retrospectively enrolled 130 patients (74 men; 60.1 ± 8.1 years) with chronic HCV treated with interferon and ribavirin therapy who achieved SVR. To evaluate the change in fibrosis stage over time, all patients underwent a pre-therapy initial biopsy and a second biopsy after achieving SVR. RESULTS: The mean time between biopsies was 5.5 ± 1.2 years. Fibrosis stage regressed in 55 patients (42.3%), remained stable in 69 (53.1%), and progressed in 6 (4.6%). The mean fibrosis stage significantly decreased, from 2.01 ± 0.99 units to 1.61 ± 1.24 units (P < 0.001). Aspartate aminotransferase, γ-glutamyltransferase, and α-fetoprotein (AFP) levels at 24 weeks after the end of treatment (EOT) were significantly lower, and the platelet count at 24 weeks after the EOT was significantly higher in patients with fibrosis regression than in those without. Logistic regression analysis confirmed that lower AFP levels (< 5.4 ng/mL) at 24 weeks after the EOT (odds ratio [OR], 4.626; 95% confidence interval [CI], 1.557-13.153; P = 0.006) and HCV genotype 2 (OR, 2.198; 95% CI, 1.010-4.786; P = 0.047) were significant independent predictive factors for regressed fibrosis after SVR. CONCLUSIONS: Lower post-treatment AFP levels and HCV genotype 2 significantly correlated with liver fibrosis regression after SVR. SN - 1440-1746 UR - https://www.unboundmedicine.com/medline/citation/27123974/α_fetoprotein_levels_after_interferon_therapy_predict_regression_of_liver_fibrosis_in_patients_with_sustained_virological_response_ L2 - https://doi.org/10.1111/jgh.13245 DB - PRIME DP - Unbound Medicine ER -